The test looks for cells that normally line the insides of blood vessels. When those cells, called endothelial cells, start to build up in the blood, researchers say they may be an early indicator of trouble.
“When they start to leak and slough off into the blood, that’s a really bad sign. They do that over the course of a few days to a couple of weeks before a heart attack occurs,” says researcher Eric J. Topol, MD, a professor of genomics and director of the Scripps Translational Science Institute in La Jolla, Calif.
Identifying Vulnerable Plaques
In recent years, doctors have developed a new understanding of heart attacks.
They once thought that arteries clog for the same reason that drain pipes do. Gunk like cholesterol that flows through them gradually sticks to the inside walls, hardening over time and narrowing the artery opening. That’s a process called stenosis, and that kind of buildup sometimes does lead to chest pain and heart attacks.
But more often, scientists believe heart attacks happen for a different reason: soft plaques.
Soft plaques are collections of liquid fats and debris that build up hidden away inside artery walls, almost like pimples.
When the layer of cells containing the plaque starts to thin, the plaque can break open. A blood clot forms in response to the plaque rupture. The clot is often what blocks the artery, causing a heart attack.
The problem with soft plaques is that they are hard to detect and may not cause any symptoms.
“Clearly the ability to predict plaque rupture and [heart attack] is one of the most difficult situations that we have in heart disease,” says Barry Kaplan, MD, vice chairman of cardiology at North Shore University Hospital in Manhasset, N.Y. and Long Island Jewish Medical Center in New Hyde Park, N.Y.
Kaplan reviewed the study for WebMD but was not involved in the research.
Test Finds Circulating Cells
The new test uses tiny, protein-coated magnets to pull circulating endothelial cells (CECs), which are normally rare, out of a blood sample.
Similar technology is used in a test for cancer patients. That test identifies circulating tumor cells, which are also rare. In cancer, the test is meant to help doctors and patients determine how aggressive a tumor may be or whether it is responding to treatment.
Study researcher Mark C. Connelly, PhD, director of cellular research at Veridex, the company that makes the test, declined to speculate on how much the experimental blood test might cost if it’s used for heart attacks.
Researchers gave the test to 50 patients who were having major heart attacks that could be confirmed by changes to their heart’s electrical rhythms and to key levels of enzymes that are indicators of heart damage.
They also gave the test to 44 blood donors who reported being free of any chronic disease.
Heart attack patients had levels of CECs that were more than four times higher than the levels seen in healthy blood donors.
There were other important differences, too. Under a microscope, the CECs seen in heart attack patients were larger and appeared to be stuck together in clusters, whereas the CECs in healthy people were smaller and appeared more often as single cells.
The study is published in the journal Science Translational Medicine.
Many Questions Remain
Experts who were not involved in the study say the results are intriguing, but note that much more work is needed before such a test could be used to predict heart attacks.
“This is an interesting observation, but it fails to demonstrate that finding these cellular patterns in blood during stable, asymptomatic phases of [heart] disease actually will predict the future risk of a heart attack,” says Prediman K. Shah, MD, director of the division of cardiology at Cedars-Sinai Medical Center in Los Angeles. Shah also directs atherosclerosis research at Cedars-Sinai.
“That’s a fundamental flaw of the study. Maybe that will be their next study, but that’s going to be a hard study to do,” says Shah, noting that such a study would require following thousands of patients at risk for heart attack, rather than testing people who’ve already had one.
Other experts agree that the test has potential but needs more research.
“I think the key word is potential,” says Suzanne Steinbaum, MD, a preventive cardiologist who directs the division of women and heart disease at Lenox Hill Hospital in New York City. “We’re really looking at people who’ve already had heart attacks. Their theory is that if we can see these cells in people before they have a heart attack, can we really diagnose those that are at risk?”
If the test checks out in future studies, Steinbaum says it could have a major impact. “I think it would change the face of how we manage heart disease, in general. It’s exciting to think about.”
Advice to Patients
Until researchers get more answers, Kaplan says there are important things patients can do to reduce their risk of a plaque rupture.
The study was co-authored by doctors and scientists from Scripps Health; STSI; TSRI; Veridex, LLC (a Johnson & Johnson company), the manufacturer of the test used in the study; Palomar Health; and Sharp HealthCare. Funding came from a $2 million grant from the National Institutes of Health.